Trial
NCT02706392
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Fred Hutchinson Cancer Center
Collaborators
National Cancer Institute (NCI)
Condition
Hematopoietic and Lymphoid Cell Neoplasm
Intervention
Laboratory Biomarker Analysis
Why stopped
Terminated due to slow accruals.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-08-31